You are here

CARMAPHARM

EN
R&D

A new generation of drugs is revolutionizing our approaches to treating disease. The first medicinal compounds were found in nature, notably in the yew for cancer drugs, but also in molds for antibiotics.  Next, humans designed and synthesized drugs – small molecules for the most part – in the chem lab.  Today, the biotechnological revolution has given rise to a new generation of therapeutic agents.  These include therapeutic monoclonal recombinant antibodies.  Their use makes it possible to treat the most serious diseases while limiting the extent of the treatment’s adverse effects.   Unfortunately, these new drugs are expensive to make.  Consequently, they are not available to everyone.  Our aim is to develop new equipment for producing and purifying manmade antibodies more cheaply.  We can make this new equipment using a production system that benefits from recent developments in microfluidics and precision machining.  That is the MT-CARMAPHARM project’s aim.

Project partners: 

Mecasoft

Undefined

UCB

Undefined

ULg / LGC

Undefined